Immune Consequences of Protracted Host-Tumor Interactions in a Transgenic Mouse Model of Mammary Carcinoma

REFERENCES

• Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003; 5: 31–36
   PubMed Web of Science ®Google Scholar
• Shekhar M. P., Pauley R., Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003; 5: 130–135
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr. Opin. Immunol. 2004; 16(2)143–150
   PubMed Web of Science ®Google Scholar
• Gendler S. J., Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol. Med. 2001; 7(10)471–475
   PubMed Web of Science ®Google Scholar
• Guy C. T., Cardiff R. D., Muller W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol. 1992; 12(3)954–961
   PubMed Web of Science ®Google Scholar
• Lin E. Y., Jones J. G., Li P., Zhu L., Whitney K. D., Muller W. J., Pollard J. W. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 2003; 163(5)2113–2126
   PubMed Web of Science ®Google Scholar
• Basu G. D., Pathangey L. B., Tinder T. L., Lagioia M., Gendler S. J., Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol. Cancer Res. 2004; 2(11)632–642
   PubMed Web of Science ®Google Scholar
• Mukherjee P., Madsen C. S., Ginardi A. R., Tinder T. L., Jacobs F., Parker J., Agrawal B., Longenecker B. M., Gendler S. J. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J. Immunother. 2003; 26(1)47–62
   PubMed Web of Science ®Google Scholar
• Knutson K. L., Dang Y., Lu H., Lukas J., Almand B., Gad E., Azeke E., Disis M. L. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 2006; 177(1)84–91
   PubMed Web of Science ®Google Scholar
• Pannellini T., Forni G., Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis. 2004; 20: 33–42
   PubMedGoogle Scholar
• Reilly R. T., Machiels J. P., Emens L. A., Ercolini A. M., Okoye F. I., Lei R. Y., Weintraub D., Jaffee E. M. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001; 61(3)880–883
   PubMed Web of Science ®Google Scholar
• Sakai Y., Morrison B. J., Burke J. D., Park J. M., Terabe M., Janik J. E., Forni G., Berzofsky J. A., Morris J. C. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 2004; 64(21)8022–8028
   PubMed Web of Science ®Google Scholar
• Astolfi A., Rolla S., Nanni P., Quaglino E., De Giovanni C., Iezzi M., Musiani P., Forni G., Lollini P. L., Cavallo F., Calogero R. A. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol. Immunother. 2005; 54(6)599–610
   PubMed Web of Science ®Google Scholar
• Ellies L. G., Fishman M., Hardison J., Kleeman J., Maglione J. E., Manner C. K., Cardiff R. D., MacLeod C. L. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int. J. Cancer. 2003; 106(1)1–7
   PubMed Web of Science ®Google Scholar
• Knutson K. L., Lu H., Stone B., Reiman J. M., Behrens M. D., Prosperi C. M., Gad E. A., Smorlesi A., Disis M. L. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J. Immunol. 2006; 177(3)1526–1533
   PubMed Web of Science ®Google Scholar
• Niemeyer C. C., Spencer-Dene B., Wu J. X., Adamson E. D. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int. J. Cancer 1999; 81(4)588–591
   PubMed Web of Science ®Google Scholar
• Qiu T. H., Chandramouli G. V., Hunter K. W., Alkharouf N. W., Green J. E., Liu E. T. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res. 2004; 64(17)5973–5981
   PubMed Web of Science ®Google Scholar
• Degl'Innocenti E., Grioni M., Boni A., Camporeale A., Bertilaccio M. T., Freschi M., Monno A., Arcelloni C., Greenberg N. M., Bellone M., Peripheral T. cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 2005; 35(1)66–75
   PubMed Web of Science ®Google Scholar
• Otahal P., Schell T. D., Hutchinson S. C., Knowles B. B., Tevethia S. S. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 2006; 177(5)3089–3099
   PubMed Web of Science ®Google Scholar
• Park J. M., Terabe M., Sakai Y., Munasinghe J., Forni G., Morris J. C., Berzofsky J. A. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J. Immunol. 2005; 174(7)4228–4236
   PubMed Web of Science ®Google Scholar
• Rowse G. J., Tempero R. M., VanLith M. L., Hollingsworth M. A., Gendler S. J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998; 58(2)315–321
   PubMed Web of Science ®Google Scholar
• Leek R. D., Harris A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia. 2002; 7(2)177–189
   PubMed Web of Science ®Google Scholar
• Luo Y., Zhou H., Krueger J., Kaplan C., Lee S. H., Dolman C., Markowitz D., Wu W., Liu C., Reisfeld R. A., Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 2006; 116(8)2132–2141
   PubMed Web of Science ®Google Scholar
• Melani C., Chiodoni C., Forni G., Colombo M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003; 102(6)2138–2145
   PubMed Web of Science ®Google Scholar
• Sinha P., Clements V. K., Miller S., Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 2005; 54(11)1137–1142
   PubMed Web of Science ®Google Scholar
• Molling J. W., Kolgen W., van der Vliet H. J., Boomsma M. F., Kruizenga H., Smorenburg C. H., Molenkamp B. G., Langendijk J. A., Leemans C. R., von Blomberg B. M., Scheper R. J., van den Eertwegh A. J. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer. 2005; 116(1)87–93
   PubMed Web of Science ®Google Scholar
• Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., Godfrey D. I., Ostrand-Rosenberg S., Smyth M. J., Berzofsky J. A. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 2005; 202(12)1627–1633
   PubMed Web of Science ®Google Scholar
• Hueman M. T., Stojadinovic A., Storrer C. E., Foley R. J., Gurney J. M., Shriver C. D., Ponniah S., Peoples G. E. Levels of circulating regulatory CD4(+)CD25 (+) T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine(bigstar). Breast Cancer Res Treat. 2006; 98(1)17–29
   PubMed Web of Science ®Google Scholar
• Liyanage U. K., Moore T. T., Joo H. G., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002; 169(5)2756–2761
   PubMed Web of Science ®Google Scholar
• Okita R., Saeki T., Takashima S., Yamaguchi Y., Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol. Rep. 2005; 14(5)1269–1273
   PubMed Web of Science ®Google Scholar
• Jackson J. R., Seed M. P., Kircher C. H., Willoughby D. A., Winkler J. D. The codependence of angiogenesis and chronic inflammation. Faseb. J. 1997; 11(6)457–465
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Miranda R., Zakarian A., Bachmann M. F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R. M., Ohashi P. S. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997; 186(5)645–653
   PubMed Web of Science ®Google Scholar
• Stewart T. J., Greeneltch K. M., Lutsiak M. E., Abrams S. I. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev. Mol. Med. 2007; 9(4)1–20
   PubMedGoogle Scholar
• Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000; 6(8)3282–3289
   PubMed Web of Science ®Google Scholar
• Lebrecht A., Grimm C., Lantzsch T., Ludwig E., Hefler L., Ulbrich E., Koelbl H. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004; 25(1–2)14–17
   PubMed Web of Science ®Google Scholar
• Fuentes M. E., Durham S. K., Swerdel M. R., Lewin A. C., Barton D. S., Megill J. R., Bravo R., Lira S. A. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J. Immunol. 1995; 155(12)5769–5776
   PubMed Web of Science ®Google Scholar
• Lu B., Rutledge B. J., Gu L., Fiorillo J., Lukacs N. W., Kunkel S. L., North R., Gerard C., Rollins B. J. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 1998; 187(4)601–608
   PubMed Web of Science ®Google Scholar
• Zhang L., Khayat A., Cheng H., Graves D. T. The pattern of monocyte recruitment in tumors is modulated by MCP-1 expression and influences the rate of tumor growth. Lab. Invest. 1997; 76(4)579–590
   PubMed Web of Science ®Google Scholar
• Burke F., Relf M., Negus R., Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine. 1996; 8(7)578–585
   PubMed Web of Science ®Google Scholar
• Naylor M. S., Stamp G. W., Foulkes W. D., Eccles D., Balkwill F. R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 1993; 91(5)2194–2206
   PubMed Web of Science ®Google Scholar
• Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L., Lewis C. E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 1998; 77(12)2246–2251
   PubMed Web of Science ®Google Scholar
• Malik S. T., Griffin D. B., Fiers W., Balkwill F. R. Paradoxical effects of tumour necrosis factor in experimental ovarian cancer. Int. J. Cancer 1989; 44(5)918–925
   PubMed Web of Science ®Google Scholar
• Malik S. T., Naylor M. S., East N., Oliff A., Balkwill F. R. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur. J. Cancer 1990; 26(10)1031–1034
   PubMed Web of Science ®Google Scholar
• Moore R. J., Owens D. M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., Kollias G., Balkwill F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999; 5(7)828–831
   PubMed Web of Science ®Google Scholar
• Negus R. P., Stamp G. W., Hadley J., Balkwill F. R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 1997; 150(5)1723–1734
   PubMed Web of Science ®Google Scholar
• Warzocha K., Salles G., Bienvenu J., Bastion Y., Dumontet C., Renard N., Neidhardt-Berard E. M., Coiffier B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 1997; 15(2)499–508
   PubMed Web of Science ®Google Scholar
• Chen D., Xia J., Tanaka Y., Chen H., Koido S., Wernet O., Mukherjee P., Gendler S. J., Kufe D., Gong J. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology. 2003; 109(2)300–307
   PubMed Web of Science ®Google Scholar
• Lin E. Y., Pollard J. W. Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004; 256: 158–168, discussion 168–172, 259–169
   PubMedGoogle Scholar
• Heys S. D., Eremin O. The relevance of tumor draining lymph nodes in cancer. Surg. Gynecol. Obstet. 1992; 174(6)533–540
   PubMedGoogle Scholar
• Lores B., Garcia-Estevez J. M., Arias C. Lymph nodes and human tumors (review). Int. J. Mol. Med. 1998; 1(4)729–733
   PubMed Web of Science ®Google Scholar
• Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 2001; 24(6)431–446
   PubMed Web of Science ®Google Scholar
• Sinha P., Clements V. K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 2005; 174(2)636–645
   PubMed Web of Science ®Google Scholar
• Kay N. E., Leong T. L., Bone N., Vesole D. H., Greipp P. R., Van Ness B., Oken M. M., Kyle R. A. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98(1)23–28
   PubMed Web of Science ®Google Scholar
• Kuss I., Hathaway B., Ferris R. L., Gooding W., Whiteside T. L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004; 10(11)3755–3762
   PubMed Web of Science ®Google Scholar
• Stewart T. J., Abrams S. I. Altered immune function during long-term Host-Tumor interactions can be modulated to retard autochthonous neoplastic growth. J. Immunol. 2007; 179(5)2851–2859
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C., Anderson D. E. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 2006; 18(2)214–219
   PubMed Web of Science ®Google Scholar
• Leong P. P., Mohammad R., Ibrahim N., Ithnin H., Abdullah M., Davis W. C., Seow H. F. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. 2006; 102(2)229–236
   PubMed Web of Science ®Google Scholar
• Ambrosino E., Spadaro M., Iezzi M., Curcio C., Forni G., Musiani P., Wei W. Z., Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 2006; 66(15)7734–7740
   PubMed Web of Science ®Google Scholar
• Yang L., DeBusk L. M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L. M., Carbone D. P., Lin P. C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6(4)409–421
   PubMed Web of Science ®Google Scholar
• Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., Zanovello P., Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 2004; 53(2)64–72
   PubMed Web of Science ®Google Scholar
• Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006; 16(1)53–65
   PubMed Web of Science ®Google Scholar
• Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357(9255)539–545
   PubMed Web of Science ®Google Scholar
• Neumark E., Sagi-Assif O., Shalmon B., Ben-Baruch A., Witz I. P. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int. J. Cancer 2003; 106(6)879–886
   PubMed Web of Science ®Google Scholar
• Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J. Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 2003; 88(11)1721–1726
   PubMed Web of Science ®Google Scholar
• Dehqanzada Z. A., Storrer C. E., Hueman M. T., Foley R. J., Harris K. A., Jama Y. H., Kao T. C., Shriver C. D., Ponniah S., Peoples G. E. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin. Cancer Res. 2006; 12(2)478–486
   PubMed Web of Science ®Google Scholar
• Sheen-Chen S. M., Chen W. J., Eng H. L., Chou F. F. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res. Treat. 1997; 43(3)211–215
   PubMed Web of Science ®Google Scholar
• Saji H., Koike M., Yamori T., Saji S., Seiki M., Matsushima K., Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001; 92(5)1085–1091
   PubMed Web of Science ®Google Scholar
• Peng L., Shu S., Krauss J. C. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res. 1997; 57(21)4849–4854
   PubMed Web of Science ®Google Scholar
• Gu L., Tseng S., Horner R. M., Tam C., Loda M., Rollins B. J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404(6776)407–411
   PubMed Web of Science ®Google Scholar
• Rutledge B. J., Rayburn H., Rosenberg R., North R. J., Gladue R. P., Corless C. L., Rollins B. J. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J. Immunol. 1995; 155(10)4838–4843
   PubMed Web of Science ®Google Scholar
• Amann B., Perabo F. G., Wirger A., Hugenschmidt H., Schultze-Seemann W. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol. 1998; 82(1)118–121
   PubMedGoogle Scholar